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ABSTRACT
Extracellular signal-regulated kinase (ERK) 1/2 signaling is involved in tumor cell survival through the regulation of Bcl-2 family members.
To explore this further and to demonstrate the central role of the mitochondria in the ERK1/2 pathway we used the HeLa cellular model where
apoptosis was induced by tumor necrosis factor (TNF) and cycloheximide (CHX). We show that HeLa cells overexpressing ERK-1 displayed
resistance to TNF and CHX. HeLa cells overexpressing a kinase-deficient form of ERK-1 (K71R) were more sensitive to TNF and CHX. In the
ERK-1 cells, Bad was phosphorylated during TNFþ CHX treatment. In the HeLa wt cells and in the K71R clones TNF and CHX decreased Bad
phosphorylation. ERK-1 cells treated with TNF and CHX did not release cytochrome c from the mitochondria. By contrast, HeLa wt and K71R
clones released cytochrome c. Bax did not translocate to the mitochondria in ERK-1 cells treated with TNFþCHX. Conversely, HeLa wt and
K71R clones accumulated Bax in the mitochondria. In the HeLa wt cells and in both ERK-1 transfectants Bid was cleaved and accumulated in
the mitochondria. The caspase-8 inhibitor IETD-FMK and the mitochondrial membrane permeabilization inhibitor bongkrekic acid (BK),
partially prevented cell death by TNFþ CHX. Anisomycin, a c-Jun N-terminal kinases activator, increased TNF-killing. The ERK-1 cells were
resistant to TNF and anisomycin, whereas K71R clones resulted more sensitive. Our study demonstrates that in HeLa cells the ERK-1 kinase
prevents TNFþCHX apoptosis by regulating the intrinsic mitochondrial pathway through different mechanisms. Inhibition of the intrinsic
pathway is sufficient to almost completely prevent cell death. J. Cell. Biochem. 108: 1166–1174, 2009.  2009 Wiley-Liss, Inc.
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E xtracellular signal-regulated kinase (ERK) 1/2 belong to themitogen-activated protein kinase (MAPK) family [Ramos,
2008]. ERK1 (p44) and ERK2 (p42) are part of intracellular
phosphorylation cascades from the cytoplasm to the nucleus recruited
for growth factor signal transduction [Raman et al., 2007; Shaul and
Seger, 2007]. In the presence of extracellular stimuli, ERK1/2 are
phosphorylated and activated upon stimulation of the Ras/Raf/MEK1/
2/ERK1/2 protein kinase cascade [Cohen et al., 2006; Kim et al., 2006;
Rouleau et al., 2009]. Such phosphorylation strongly increases ERK1/
2 activity, induces its nuclear translocation, and subsequently
triggers-specific gene expression [Kondoh et al., 2005]. Upon its
activation, the cascade is involved in many cellular processes, such as
proliferation, differentiation, migration, cell survival, and apoptosis
[Lu and Xu, 2006]. Typically, the magnitude and duration of ERK1/2
activity is determined by the balance between the activity of MEK1/2,
the kinases that phosphorylate and activate ERK1/2, and the activity
of phosphatases that can dephosphorylate and inactivate ERK1/2
[Kondoh and Nishida, 2007].
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C-Jun N-terminal kinases (JNKs) are another subfamily of
proteins belonging to the MAP kinase family. The JNKs signaling
pathway can be stimulated by a variety of stresses [Johnson and
Nakamura, 2007]. These include genotoxic stress, heat shock,
osmotic shock, and metabolic stress, as well as pro-inflammatory
cytokines, such as tumor necrosis factor (TNF) and interleukin 1-
beta [Weston and Davis, 2007]. JNKs phosphorylate transcription
factors c-Jun, ATF-2, p53, Elk-1, which in turn regulate the
expression of genes involved in cell proliferation, differentiation,
and apoptosis [Dhanasekaran and Reddy, 2008; Yang and
Trevillyan, 2008].
Apoptosis or programmed cell death (PCD) is a series of
biochemical and morphological alterations leading to cellular
dismantling through ATP-dependent mechanisms. Apoptosis can be
activated by intrinsic stress, such as growth factor deprivation or cell
damages, or by extrinsic mechanisms such as activation of death
receptors [Strasser et al., 2000]. The ultimate decision to activate the
suicide program is controlled by the Bcl-2 protein family [Gross
et al., 1999]. Bcl-2 family members are divided into three
subfamilies; pro-survival (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and A1),
pro-apoptotic (Bax, Bak, and Bok), and BH3 pro-apoptotic (Bad, Bid,
Bik, Blk, Hrk, BNIP3, and BimL) [Petros et al., 2004; Youle and
Strasser, 2008]. The pro-apoptotic Bcl-2 proteins are often found in
the cytosol, where they act as sensors of cellular damage or stress.
During apoptosis they relocate to the surface of the mitochondria,
where they induce the permeabilization of the mitochondrial
membrane with the release of cytochrome c and the formation of the
apoptosome [Sharpe et al., 2004]. The apoptosome is a cytosolic
complex formed by the interaction between cytochrome c, pro-
caspase-9, and APAF-1. Clustering and activation of pro-caspase-9
leads to activation of caspase-3 [Breckenridge and Xue, 2004],
which in turn promotes a number of morphological changes
including cell shrinkage, chromatin condensation, DNA fragmenta-
tion, and plasma membrane blebbing [Orrenius, 2004].
The present study investigates the role of ERK-1 in the cell killing
of HeLa cells by TNF and cycloheximide (CHX). We show that
overexpression of ERK-1 reduces TNF toxicity through phosphor-
ylation of the pro-apoptotic protein Bad and inhibition of the
mitochondria permeability transition (MPT). Overexpression of a
kinase-deficient ERK-1 (K71R) greatly increased cell killing by TNF
and CHX. Finally, cell killing could be completely prevented by
simultaneously inhibiting both caspase-8 activity and MPT
induction.
MATERIALS AND METHODS
CELL LINE
HeLa cells (human cervix adenocarcinoma, ATCC-CC-1, Rockville,
MD) were maintained in 25-cm2 polystyrene flasks (Corning Costar
Corp., Oneonta, NY) with 5ml of Dulbecco’s modified Eagle’s
Minimummedium (DMEM;Mediatech, Inc., Hedron, VA) containing
100U/ml penicillin, 0.1mg/ml streptomycin, and 10% heat-
inactivated fetal bovine serum. The cells were incubated under an
atmosphere of 95% air and 5% CO2. For all experiments, HeLa cells
were plated at a density of 40,000 cells/cm2 in complete DMEM.
Following overnight incubation, the cells were washed once with
PBS and placed in DMEM without serum.
TREATMENTS
Human recombinant TNF-alpha (Sigma, St. Louis, MO) was
dissolved in PBS and added at 10 ng/ml for the times indicated.
CHX (Sigma) was dissolved in PBS and added at 10mM for the times
indicated. The caspase-8 inhibitor Z-Ile-Glu(OMe)-Thr-Asp(OMe)-
CH2F (IETD) (Kamiya Biomedical, Seattle, WA) was dissolved
in Me2SO and added at a final concentration of 50mM. In all cases,
when diluted to a final concentration of 0.1% (v/v), Me2SO had no
effect on the cells or the parameters measured. Anisomycin (Enzo
Life Sciences, Plymouth Meeting, PA) was dissolved in Me2SO and
added to a final concentration of 10mg/ml. Bongkrekic acid (BK)
(Merck Chemicals, Nottingham, UK) was dissolved in 2N NH4OH and
added at a final concentration of 40mM. NH4OH alone had no effect
on the cells or the parameters measured.
CELL VIABILITY ASSAY
Cell viability was determined at the times indicated by the release of
lactate dehydrogenase (LDH) into the culture medium as described
previously [Pastorino et al., 1995].
GENERATION OF STABLE ERK-1 TRANSFECTANTS
HeLa cells were plated in 1.88 cm2 wells of a 24-well plate. After an
overnight incubation, the cells were washed once with PBS and then
transfected using Lipofectomine-PLUS (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. The cells were
transfected with 0.5mg of pCDNA-Erk-1 wt and pCDNA-Erk-1
K71R (kinase-deficient form of Erk-1). The pCEP4L-Erk-1 wt and
pCEP4L-Erk-1 K71R plasmids were generously provided by Dr.
Melanie Cobb, University of Texas Southwestern Medical Center
[Frost et al., 1994]. Erk-1 wt cDNA and Erk-1 K71R cDNA were
subcloned into the pCDNA3.1 vector (Invitrogen). After 4 h the cells
were washed twice with PBS and placed into complete DMEM and
incubated for 48 h. The cells were then washed once with PBS and
trypsinized. Four wells of Erk-1 wt transfected cells and four wells of
the Erk-1 K71R transfected cells were placed respectively into two
75-cm2 polystyrene flasks in complete DMEM supplemented with
860mg/ml of G418 (Invitrogen). Stable transfectants were generated
and cultured in 25-cm2 polystyrene flasks. The overexpression of the
HA-tagged Erk-1 wt and the overexpression of the HA-tagged Erk-1
K71R were confirmed by Western Blot analysis. Approximately
1 106 cells were collected and pelleted at 1,000g (10min at 48C)
and a total lysate was obtained. A sample containing (30mg)
of proteins was separated by electrophoresis on a 10% SDS–
polyacrylamide gel. The gel was electroblotted onto a Trans-Blot
Transfer Medium pure nitrocellulose membrane (0.45mm) (Bio-Rad,
Hercules, CA). The blot was probed with an anti-HA rabbit
polyclonal antibody (Y-11) (Santa Cruz Biotechnology, Santa Cruz,
CA) at a dilution of 1:4,000. The membrane was incubated with a
secondary anti-rabbit horseradish peroxidase-labeled antibody
(1:20,000); the protein–antibody complex was visualized by
enhanced chemiluminescence.
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WHOLE CELL LYSATE
After treatment the cells were harvested by scraping, pelleted by
centrifugation at 1,000g (10min at 48C), and then resuspended in
50–100ml cell lysis buffer (20mM Tris pH 7.4, 100mM NaCl, 1%
Triton) with Proteinase Inhibitors (1mM phenylmethylsulfonyl
fluoride, 10mg/ml leupeptin, 10mg/ml aprotinin). The sample was
centrifuged at 14,000g (10min at 48C) to remove debris and
unbroken cells.
ISOLATION OF CYTOSOL AND MITOCHONDRIAL FRACTIONS
Cells were plated in 75-cm2 polystyrene flasks. Following treatment
the cells were harvested by centrifugation at 750g for 10min at 48C.
The cell pellets were resuspended in 1ml of 20mM HEPES–KOH (pH
7.5), 10mM KCl, 1.5mM MgCl2, 1mM EDTA, 1mM EGTA, 1mM
phenylmethylsulfonyl fluoride, 10mg/ml leupeptin, 10mg/ml
aprotinin, and 250mM sucrose. The cells were rupture by six
passages through a 26.5-gauge needle applied to a 1ml syringe. The
disrupted cells were centrifuged at 750g for 10min at 48C. The pellet
obtained was resuspended in PBS and stained with Trypan blue in
order to identify unbroken cells. Over 95% of the cells were
disrupted as evidenced by their uptake of the dye. The supernatant
was transferred to a high-speed centrifuge tube. Centrifugation was
conducted at 10,000g for 30min at 48C. The resulting mitochondrial
pellet was lysed in 50ml of 20mM Tris, pH 7.4, 100mM NaCl, 1mM
phenylmethylsulfonyl fluoride, 10mg/ml leupeptin, 10mg/ml
aprotinin, and 1% Triton X-100. The supernatant from the
10,000g spin was centrifuged at 100,000g (60min at 48C), and
the supernatant was used for preparation of cytosol. The cytosolic
fraction was concentrated through a Microcon YM-10 Centrifugal
Filter Device (Millipore, Milan, Italy). Protein content of the
fractions was determined by the bicinchoninic acid assay (Sigma).
WESTERN BLOT ANALYSIS
Equivalent amounts of protein were electrophoresed on SDS–
polyacrylamide gels. Kaleidoscope Prestained Standards (Bio-Rad)
were used to determine molecular weight. The gels were electro-
blotted onto nitrocellulose membranes and probed with the
following primary antibodies [Bax N-20 (Santa Cruz Biotechnology)
1:1,000, Bid (Biosource, Camarillo, CA), Bad C-7 (Santa Cruz
Biotechnology) 1:500, PhosphoBad Ser-136 (Cell Signaling Tech-
nology, Beverly, MA) 1:500, Elk-1 and PhosphoElk-1 Ser 383 (Santa
Cruz Biotechnology) 1:500, cytochrome c (BD International, Milan,
Italy) 1:500, COX4 (Invitrogen) 1:1,000, actin C-2 (Santa Cruz
Biotechnology) 1:400]. The membrane was incubated with a
secondary anti-mouse (1:15,000) or anti-rabbit (1:15,000) horse-
radish peroxidase-labeled antibody. The protein–antibody complex
was visualized by enhanced chemiluminescence.
ISOLATION OF NUCLEAR FRACTION
Cells (2 106) were plated in 100mm dishes. The nuclear and
cytosolic fractions were isolated using the nuclear extraction kit
from Active Motif (Carlsbad, CA) following manufacturer’s
instructions. Briefly, following treatment, cells were scraped off
the plate in a PBS/phosphatase inhibitor buffer using a rubber
policeman. Cells were centrifuged 5min at 500 rpm at 48C and the
supernatant discarded. The cell pellet was lysed in hypotonic buffer
for 15min in ice followed by centrifugation (30 s at 14,000 rpm at
48C). The supernatant (cytosolic fraction) was transferred to a new
tube, while the pellet (nuclear fraction) was lysed in a lysis buffer in
the presence of protease inhibitors.
ELISA ASSAY
Nuclear extracts were obtained as described above and used to
measure the relative amount of phosphorylated Elk-1 using the
TransAM kit from Active Motif and following manufacturer’s
instructions. Briefly, equivalent amounts of protein from nuclear
extracts were loaded on a 96-well plate coated with oligonucleotides
containing consensus-binding site for Elk-1. After 1 h incubation at
room temperature, wells were washed three times in wash buffer and
incubated 1 h with a primary antibody against phosphorylated Elk-1
at room temperature. Subsequently, wells were washed and
incubated 1 h with HRP-conjugated secondary antibody followed
by the addition of a developing solution. A stop solution was added
to block the reaction and the color intensity was read in a plate
reader with a 450 nm filter. The color intensity in each well is
proportional to the amount of the transcription factor bound to the
oligonucleotides.
STATISTICAL ANALYSIS
All experiments were repeated 3–5 times. Significant differences
between sets of values for control and test groups were assessed by a
one-way ANOVA using a student Newman–Keuls post hoc test. A P-
value refers to a comparison of a measured parameter in the
experimental group with that of the appropriate control; sig-
nificance was set at P< 0.05.
RESULTS
OVEREXPRESSION OF ERK-1 PREVENTS CELL KILLING BY
TNFR CHX
Clones of stably transfected HeLa cells were produced that
overexpress either the wild-type ERK-1 protein (ERK-1) or a
kinase-deficient form of ERK-1 (ERK-1 K71R) bearing a hemagglu-
tinin tag (HA) (Fig. 1A). The sensitivity of these clones to TNF and
CHX is shown in Figure 1B. Treatment of wild-type HeLa cells for
24 h with TNF and CHX killed 60% of the cells. The same doses of
TNF and CHX, however, killed only 25% of the ERK-1 over-
expressing HeLa cells and 74% of the HeLa cells overexpressing the
kinase-deficient form of ERK-1 (Fig. 1B). Supplementary Figure 1
shows that treatment of wild-type HeLa cells or ERK clones with TNF
or CHX alone did not induce a significant increase in the number of
dead cells.
A well-known ERK-1 and ERK-2 substrate is Elk-1. Elk-1 is a
transcription factor that, along with Sap1 and Net, forms the ternary
complex factor (TCF) involved in regulating gene expression by
DNA binding at the serum-response elements (SRE) [Buchwalter
et al., 2004]. The DNA binding activity of Elk-1 is regulated through
phosphorylation on serine 383 residue by ERK1/2. Therefore, we
used the phosphorylation state of Elk-1 on serine 383 to measure
the kinase activity of our ERK-1 clones. In particular, we used
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to separate techniques, Western blot assay with an antibody
recognizing phosphorylated Elk-1 and the Elk-1 transcription factor
assay kit. Figure 1C shows that ERK-1 overexpressing cells had
an increased phosphorylated Elk-1 whereas, in ERK-1 K71R
cells phosphorylation of Elk-1 on Ser 383 was greatly reduced.
Similarly, Figure 1D shows that DNA binding activity of
phosphorylated Elk-1 was increased in ERK-1 overexpressing cells,
while being significantly reduced in ERK-1 K71R cells. Finally, TNF
and CHX treatment reduced Elk-1-DNA binding activity in HeLa wt
and ERK-1 K71R cells but not in the ERK-1 overexpressing cells
(Fig. 1D).
OVEREXPRESSION OF ERK-1 PREVENTS BAD
DE-PHOSPHORYLATION IN RESPONSE TO TNFR CHX
The BH-3 only pro-apoptotic protein Bad is localized in the cytosol
where it associates with the molecular chaperone protein 14-3-3
[Tzivion et al., 2001]. Such an association is achieved through the
phosphorylation of Bad on serine residues [Zha et al., 1996]. Upon its
phosphorylation, Bad cannot bind to the anti-apoptotic proteins
Bcl-xL or Bcl-2 that can, therefore, elicit their pro-survival activity
[Zha et al., 1996]. Either directly or indirectly, ERK proteins are
involved in the survival pathways involving the phosphorylation of
Bad [Scheid et al., 1999; Chen et al., 2008].
Fig. 1. TNFþ CHX killing and ERK-1 activity in wild-type, ERK-1 and ERK-1 K71R HeLa cells. A: HeLa cells (ERK-1 and ERK-1 K71R) were stably transfected with an ERK-1
expression vector as described in Materials and Methods Section. Expression of ERK-1 and ERK-1 K71R was determined by Western blot analysis. WT, wild-type cells. B: Wild-
type, ERK-1 and ERK-1 K71R HeLa cells were treated with TNF and CHX for 24 h. Viability of the cells was determined by LDH release. Results are the mean SD of three separate
experiments. Statistically different from the control group (P< 0.05). #Statistically different from the control, HeLa WT Tþ C and HeLa ERK-1 K71R Tþ C group (P< 0.05).
^Statistically different from the control and the HeLaWT Tþ C group (P< 0.05). C: Wild-type, ERK-1 and ERK-1 K71R HeLa cells were either left untreated or treated with TNF
and CHX for 6 h. Phosphorylation of Elk-1 on serine 383 as well as total Elk-1 content was determined by Western blot analysis. The Western blot shown is representative of
three repeats. D: Nuclear fractions were obtained from wild-type, ERK-1 and ERK-1 K71R HeLa cells either left untreated or treated with TNF and CHX for 6 h. The amount of
oligonucleotide-bound phosphorylated Elk-1 was measured by the ELISA-based TransAM method. Results are the mean SD of three separate experiments. Statistically
different from the control wild-type group (P< 0.05).
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Therefore, the phosphorylation of Bad at both Ser-112 and Ser-
136 was studied after treating the wild-type HeLa cells and the ERK
clones with TNF. As shown in Figure 2, treatment of wild-type HeLa
cells with TNF and CHX for 1 h resulted in de-phosphorylation of
Bad on both Ser-112 and Ser-136 without any change in total
amount of the protein. By contrast, Bad remained phosphorylated on
Ser-112 and Ser-136 in the ERK-1 overexpressing HeLa cells during
the treatment with TNF and CHX for 1 h (Fig. 2). HeLa cells
overexpressing the kinase-deficient form of ERK-1 (K71R) showed a
decreased constitutive phosphorylation of Bad on both Ser-112 and
Ser-136 that was completely inhibited by 1 h treatment with TNF
and CHX (Fig. 2).
OVEREXPRESSION OF ERK-1 PREVENTS CYTOCHROME C RELEASE
The release of cytochrome c from the mitochondria into the cytosol
is a widely used marker of mitochondrial alterations in apoptosis,
including the MPT. Figure 3 shows that treatment of wild-type HeLa
cells with TNF and CHX produced a decrease in the mitochondrial
content of cytochrome c that was evident after 3 h. The depletion of
cytochrome c from the mitochondrial fraction was accompanied by
an increase of this protein in the cytosolic fraction (Fig. 3). A similar
release of cytochrome c from the mitochondria to the cytosol was
observed with the HeLa cells overexpressing the kinase-deficient
ERK-1 (K71R) (Fig. 3). By contrast, overexpression of ERK-1
inhibited the release of cytochrome c by TNF and CHX treatment
(Fig. 3). In fact, the ERK-1 overexpressing HeLa cells did not show
any cytosolic accumulation of cytochrome c following 3 h treatment
with TNF and CHX (Fig. 3). Figure 3 shows that neither the content of
the mitochondrial marker protein COX4 nor that of the cytosolic
marker protein b-actin varied under the conditions studied.
OVEREXPRESSION OF ERK-1 PREVENTS TRANSLOCATION OF
BAX TO THE MITOCHONDRIA
The pro-apoptotic protein Bax translocates from the cytosol to the
mitochondria under a variety of stimuli [Pastorino et al., 1999;
Tafani et al., 2001]. Figure 4 shows that treatment of wild-type HeLa
cells with TNF and CHX for 3 h caused a redistribution of Bax from
the cytosol to the mitochondria. A similar result was obtained with
the HeLa cell line overexpressing the kinase-deficient ERK-1 (K71R)
(Fig. 4). By contrast, when the HeLa cells overexpressing ERK-1 were
treated with TNF and CHX the content of Bax did not increase in the
mitochondria or decreased in the cytosol (Fig. 4). Figure 4 shows that
neither the content of the mitochondrial marker protein COX4 nor
that of the cytosolic marker protein b-actin varied under the
conditions studied.
OVEREXPRESSION OF ERK-1 DOES NOT PREVENT BID
CLEAVAGE BY TNFR CHX
The pro-apoptotic protein Bid is expressed constitutively in HeLa
cells. TNF and CHX treatment for 3 h caused the cleavage of Bid by
Fig. 2. Phosphorylation of Bad at Ser-112 and Ser-136 in wild-type and
HeLa cells overexpressing ERK-1 or ERK-1 K71R. Wild-type, ERK-1 and ERK-1
K71R HeLa cells were treated with TNF and CHX for 1 h. Phosphorylation of Bad
at Ser-112 and Ser-136, as well as the total Bad content, was determined by
Western blot analysis as described in Materials and Methods Section. The
Western blot shown is representative of three repeats.
Fig. 3. Release of cytochrome c from mitochondria in wild-type and HeLa
cells overexpressing ERK-1 or ERK-1 K71R. Wild-type, ERK-1 and ERK-1 K71R
HeLa cells were treated with TNF and CHX for 3 h. The content of cytochrome c,
b-actin, and COX4 in the cytosolic and mitochondrial subcellular fractions was
determined by Western blot assay as described in Materials and Methods
Section. The Western blot shown is representative of three repeats.
Fig. 4. Translocation of Bax from the cytosol to the mitochondria in wild-
type and HeLa cells overexpressing ERK-1 or ERK-1 K71R. Wild-type, ERK-1
and ERK-1 K71R HeLa cells were treated with TNF and CHX for 3 h. The content
of Bax, b-actin, and COX4 in the cytosolic and mitochondrial subcellular
fractions was determined by Western blot assay as described in Materials and
Methods Section. The Western blot shown is representative of three repeats.
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caspase-8 to form truncated Bid (tBid) that, in turn, accumulated in
both the mitochondria and the cytosol (Fig. 5). Figure 5 compares
the cleavage of Bid and the accumulation of tBid in the
mitochondrial and cytosolic fractions of HeLa cell wild-type, HeLa
cells overexpressing ERK-1, and HeLa cells overexpressing the
kinase-deficient form of ERK-1 (K71R). Bid was cleaved and tBid
accumulated in the mitochondria in both the HeLa wild-type and the
HeLa ERK-1 K71R (Fig. 5). Overexpression of ERK-1 resulted in a
slight inhibition of tBid accumulation in the mitochondria, probably
owing to the absence of cytochrome c release and caspase-3
activation in these cells as observed in Figure 3 (Fig. 5). Figure 5
shows that neither the content of the mitochondrial marker protein
COX4 nor that of the cytosolic marker protein b-actin varied under
the conditions studied.
OVEREXPRESSION OF ERK-1 AND INHIBITION OF CASPASE-8
COMPLETELY PREVENTS CELL KILLING BY TNFR CHX
TNF and CHX treatment of HeLa cells activates the apoptotic
program both through the death receptor extrinsic and the
mitochondria-dependent intrinsic pathway [Shi and Shen, 2008].
In order to study the role of each of these two pathways, HeLa cell
wild-type, HeLa cells overexpressing ERK-1 and HeLa cells
overexpressing the kinase-deficient form of ERK-1 (K71R) were
treated for 24 h with TNFþCHX in the presence of the caspase-8
inhibitor IETD, the MPT inhibitor BK, or the two together. Figure 6
shows that treatment of HeLa wt cells with TNFþCHX and IETD or
BK resulted in about 50% inhibition of cell death. However, when
IETD and BK were both added to the cell culture, they completely
prevented cell killing. Similarly, in HeLa cells overexpressing ERK
K71R, IETD, or BK treatment protected 50% of the cells from TNF
toxicity. When IETD and BK were added simultaneously, the
percentage of cell killing was similar to that of the control. By
contrast, in HeLa cells overexpressing ERK-1 the protection afforded
by the BK was minimal because the mechanism of action of this
molecule (MPT inhibition) is very similar to the one obtained
through ERK-1 overexpression. In fact, in these cells, IETD alone was
able to reduce the extent of cell death to that of the control (Fig. 6).
OVEREXPRESSION OF ERK-1 PREVENTS CELL KILLING BY
TNFRANISOMYCIN
JNK kinases are activated in response to a variety of cell stresses
[Weston and Davis, 2007]. JNK kinases pathway has been shown to
be activated during apoptosis [Dhanasekaran and Reddy, 2008].
Therefore, the pro-apoptotic action of the JNK kinases can be seen as
opposed to the pro-survival action of the ERK kinases. Anisomycin
is a well-known JNK activator that has been shown to induce
apoptosis in many cell lines. Figure 7 shows that treatment of HeLa
wt cells with TNF and anisomycin for 24 h resulted in a 38% cell
death induction. The same dose of TNF and anisomycin, however,
killed only 20% of the cells overexpressing the ERK-1 protein and
70% of the ERK-1 (K71R) cells (Fig. 7). Importantly, anisomycin
alone did not significantly increase the percentage of cell death
(Fig. 7).
Fig. 5. Cleavage of Bid and translocation of tBid from the cytosol to the
mitochondria in wild-type, ERK-1 and ERK-1 K71R HeLa cells. Wild-type, ERK-
1 and ERK-1 K71R HeLa cells were treated with TNF and CHX for 3 h. The
content of Bid, b-actin, and COX4 in the cytosolic and mitochondrial sub-
cellular fractions was determined by Western blot assay as described in
Materials and Methods Section. The Western blot shown is representative
of three repeats.
Fig. 6. Prevention by IETD and BK of the killing of wild-type, ERK-1 and ERK-
1 K71R HeLa cells by TNFþ CHX. Wild-type, ERK-1 and ERK-1 K71R HeLa cells
were treated with TNF and CHX for 24 h. Viability of the cells was determined as
described under Materials and Methods Section. Results are the mean SD of
three separate experiments. Statistically different from the control of the
corresponding group (P< 0.05).
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DISCUSSION
In a previous work from our group we have shown that HeLa
cells constitute a useful cellular model to study both the growth
factor and the cytotoxic effects of TNF-a [Pastorino et al., 1999].
Furthermore, we showed that TNF-induced phosphorylation of
Bad on serine 136 by activating the phosphatidylinositide-
3-OH kinase (PI3K)-dependent pathway. In particular, PI3K
signaling would lead to activation of the serine/threonine kinase
Akt that, in turn, phosphorylates Bad on serine 136 [Pastorino et al.,
1999]. We also showed that the PI3K-Akt pathway, once over-
expressed, increased resistance of HeLa cells to other apoptotic
stimuli such as staurosporine [Tafani et al., 2001]. Recently, also
the ERK1/2 pathway has been shown to be a fundamental
survival pathway that can substitute or accompany the PI3K-Akt
signaling [Balmanno and Cook, 2009]. In light of our detailed
knowledge of the pathways activated by TNF in the HeLa cell system,
we decided to use this same cell line to study the mechanism through
which ERK1/2 signaling regulates TNF toxicity. Such an approach
allowed us to compare three of the main cellular pathway activated
by TNF: PI3K-Akt, ERK-1, and JNK. We acknowledge the fact that
our study is restricted to a single cell line, however, we also
considered that so far many tumors and tumor cell lines have been
shown to depend on the activation or overexpression of ERK1/2
pathway for their survival [Wu et al., 2004; Balmanno and Cook,
2009].
Herewith we show that overexpression of ERK-1 in HeLa cells
prevents only the intrinsic mitochondrial-dependent apoptotic
pathway activated by TNF and CHX and that such a pathway plays a
major role in carrying on the apoptotic program. In particular, we
showed that, during TNF and CHX treatment, HeLa ERK-1
overexpressing cells maintained Bad phosphorylated and did not
show any MPT induction, as measured by mitochondrial transloca-
tion of Bax and cytochrome c release. By contrast, TNF and CHX
treatment of HeLa cells overexpressing a kinase-deficient ERK-1 (K-
71R) resulted in an increased mitochondrial-dependent apoptotic
pathway that was preceded by Bad de-phosphorylation, intracellular
redistribution of Bax, and cytochrome c release.
The pro-apoptotic protein Bad has been implicated in the
induction of the apoptotic pathway by several stimuli [Tafani et al.,
2001; Sastry et al., 2006]. In fact, phosphorylation of Bad on serine
112 and 136 results in its cytoplasmic localization and dissociation
from Bcl-xL which, in turn, can bind and inactivate the pro-
apoptotic protein Bax [Zha et al., 1996]. Here we show that ERK-1 is
involved in the phosphorylation of Bad at Ser-112 and Ser-136. Bad
phosphorylation by ERK-1 allows for the inhibition of the intrinsic
apoptotic pathway activated by TNF and CHX. Further studies will
be necessary, however, to evaluate if the phosphoylation of Bad by
ERK-1 is a direct or indirect effect. In fact, while phosphorylation of
Ser-112 has been shown to depend by ERK-1, Ser-136 is believed to
depend on AKT activity [Scheid et al., 1999]. The observation that
Bad is de-phopshorylated on Ser-136 in HeLa cells overexpressing
a kinase-deficient ERK-1, suggests that this kinase may be also
involved in such a process.
The anti-apoptotic effect of ERK-1 overexpression resulted in a
significant inhibition of cell death by TNF and CHX (Fig. 1). TNF and
CHX treatment, however, still killed 25% of the ERK-1 over-
expressing HeLa cell. Therefore, we studied the role of the pro-
apoptotic protein Bid. Following the activation of the extrinsic
apoptotic pathway, Bid is cleaved by active caspase-8 generating a
truncated form called tBID [Li et al., 1998; Luo et al., 1998]. Both full
length and truncated Bid can translocate to the mitochondria,
thereby inducing the release of cytochrome c and the activation of
downstream caspases such as caspase-3. However, tBid can also be
formed by a loop as a result of the activation of caspase-8 by
activated caspase-3. Our results show that ERK-1 overexpression
can prevent such a loop without affecting the caspase-8-dependent
formation of tBid. In fact, in HeLa cells overexpressing ERK-1, there
was only a reduction of Bid cleavage, and some tBid still
accumulated in both the cytosolic and mitochondrial subcellular
fractions (Fig. 5). The role of ERK-1 in caspase-8 activation and MPT
induction was demonstrated by treating HeLa cells with IETD and
BK. We showed that ERK-1 controls the intrinsic apoptotic pathway
by inhibiting the translocation of Bax and the induction of the MPT.
However, ERK-1 did not prevent the cleavage of Bid by caspase-8
following activation of the TNF receptor. In fact, treatment of HeLa
ERK-1 cells with the caspase-8 inhibitor IETD completely prevented
the cell killing by TNF and CHX (Fig. 6). This same result was
obtained in HeLa wt cells when both caspase-8 activation and MPT
induction were inhibited by treating cells with IETD and BK (Fig. 6).
Elevated levels of dually phosphorylated (active) ERK-1/ERK-2 have
been reported in several human cancers, including colon, prostate,
Fig. 7. TNFþ anisomycin killing of wild-type, ERK-1 and ERK-1 K71R HeLa
cells. Wild-type, ERK-1 and ERK-1 K71R HeLa cells were treated with TNF and
anisomycin for 24 h. Viability of the cells was determined as described under
Materials and Methods Section. Results are the mean SD of three separate
experiments. Statistically different from the control group (P< 0.05).
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renal cell, and breast adenocarcinomas, as well as in head and neck
squamous-cell carcinoma, glial neoplasm, and melanoma [Handra-
Luca et al., 2003; Zhang et al., 2004; Li and Yang, 2009]. In
particular, ERK1/2 and its phosphorylated form have been shown to
represent an important biological marker in breast carcinoma and
gallbladder adenocarcinoma [Zhang et al., 2004; Li and Yang, 2009].
Furthermore, it is worth noting that sorafenib, a ERK1/2 inhibitor, is
a drug approved for the treatment of primary kidney cancer and
advanced primary liver cancer. Similarly, another ERK1/2 inhibitor,
AZD6244 is entering phase II clinical trial. In this context, our study
provides an important contribute to understand the role of ERK-1-
Bcl-2 family-mitochondria axis in HeLa cells exposed to TNF and
offer a cellular model to understand the mechanism of action of
newly synthesized ERK1/2 inhibitors. Furthermore, a combined
approach based on recombinant ligands or mAbs for TNF and ERK1/
2 inhibitors could prove beneficial against tumors with altered
ERK1/2 signaling.
The c Jun N-terminal kinase or JNK is involved in the apoptotic
pathway activated by different stimuli [Weston and Davis, 2007;
Dhanasekaran and Reddy, 2008]. JNK has been shown to
phosphorylate and inactivate the anti-apoptotic protein Bcl-2,
thereby inducing the MPT [Basu et al., 2000; Deng et al., 2001].
Therefore, we expected to have a similar percentage of cell killing by
substituting CHX with anisomycin in the presence of TNF. In fact,
TNFþCHX causes cell death by decreasing the activity of ERK-1,
whereas TNFþ anisomycin causes cell death by increasing the
activity of JNK. Furthermore, we expected overexpression of ERK-1
to prevent cell killing induced by anisomycin. Our results show that
ERK-1, by preventing the induction of MPT, can inhibit the JNK pro-
apoptotic pathway. In fact, overexpression of ERK-1 in HeLa cells
prevented the apoptotic pathway activated by the JNK agonist
anisomycin. HeLa ERK-1 cells showed a significant reduction in cell
death when treated with TNF and anisomycin (Fig. 7). By contrast,
HeLa ERK-1 K71R cells showed an increased sensitivity to TNF and
anisomycin (Fig. 7).
In HeLa cells TNF alone does not induce cell death probably
because of the activation of NF-kB by ERK1/2 and AP-1 by JNK.
However, when a protein synthesis inhibitor such as CHX is added,
the cell killing properties of TNF prevail. Supplemental Figure 2
represents, schematically, the known survival and apoptotic events
activated by TNF. The possible pathways and manipulations
discussed above have been inserted in the scheme and the major
players and events controlling cell survival or death evidenced in
bold. In particular, our results show that activation of ERK-1
represents a fundamental event for cell survival following activation
of the TNF receptor by TNF-a. In fact, supplemental Figure 2 shows
that the major targets of the intracellular events regulated by ERK-1
are the mitochondria that maintain their membrane potential status.
This ERK-1 pro-survival effect overcomes pro-apoptotic situations
such as JNK activation or death receptor activation and, therefore,
explains the resistance of tumor cells to several pro-apoptotic
stimuli.
The possible implications of our system where we overexpress a
wt or kinase-deficient form of ERK-1 and observe the effects on cell
survival, become clear if one considers that many tumors
overexpress ERK1/2 proteins and that this correlates with tumor
progression [Chen et al., 2004] or can be used as an independent
prognostic predictor [Li and Yang, 2009].
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